Publisher: Informa Healthcare
ISSN: 1354-3776
Source: Expert Opinion on Therapeutic Patents, Vol.7, Iss.3, 1997-03, pp. : 277-280
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This patent, from Ciba-Geigy AG, discloses a series of phosphono substituted tetrazole derivatives as ECE inhibitors and claims them as useful in the treatment of pulmonary hypertension, cerebral ischaemia, subarachnoid haemorrhage, renal failure, atherosclerosis, cerebral vasospasm, arterial hypertrophy, restenosis, arrhythmia and myocardial infarction, endotoxic shock, pre-eclampsia, diabetes (e.g., diabetic nephropathy) and Raynaud's disease
Related content
Isoforms of endothelin-converting enzyme: why and where?
By Turner A.J. Barnes K. Schweizer A. Valdenaire O.
Trends in Pharmacological Sciences, Vol. 19, Iss. 12, 1998-12 ,pp. :